Determination of antimicrobial efficacy of *Triphala Ashchyotana* as a therapeutic agent for acute conjunctivitis

Perera BSR\(^1\), Dayarathna MTA\(^2\), Perera BPR\(^2\), Karunarathne EDC\(^3\), Sudesh ADH\(^3\)

\(^1\)Department of Shalya Shalakya, Gampaha Wickramarachchi Ayurveda Institute, University of Kelaniya, Yakkala, Sri Lanka

\(^2\)Department of Cikitsa, Gampaha Wickramarachchi Ayurveda Institute, University of Kelaniya, Yakkala, Sri Lanka

\(^3\)Central Laboratory, Gampaha Wickramarachchi Ayurveda Institute, University of Kelaniya, Yakkala, Sri Lanka

**Abstract**

*Triphala* decoction is a therapeutic agent used in the form of *Ashchyotana* (eye drops) for acute conjunctivitis. The antibacterial assay was performed according to the standard Antibiotic Sensitivity Test (ABST) for *Staphylococcus aureus* (ATCC 25923), *Escherichia coli*, *Pseudomonas aeruginosa*, Methicillin Resistant *Staphylococcus aureus* (MRSA) and *Candida albicans* using chloramphenicol and fluconazole as positive controls. The test drug, *Triphala* decoction, was prepared by boiling dry samples of *Terminalia chebula*, *Terminalia belerica* and *Phyllanthus emblica* 20g each, in 1920ml of water and reducing it to 240ml. Based on the results of ABST, the Minimum Inhibitory Concentration (MIC) and Minimum Lethal Concentration (MLC) against *S. aureus* was determined by using a concentration series ranging from 3 X 50 μl to 12 X 50 μl of *Triphala* decoction with 100μl of *S. aureus* in 10ml of nutrient broth. The volumes were equalized up to 11ml using sterilized distilled water. After an overnight, incubation at 37°C, 500μl from each concentration was plated using pour-plate technique and incubated overnight at 37°C. To determine the MLC, a loopful of each concentration was streaked on Nutrient Agar plates and incubated overnight at 37°C. According to the results, *S. aureus* was sensitive to *Triphala* decoction making an inhibition zone diameter (IZD) of 18mm, while the readings for the other species were in the intermediate range of 17mm for *E.coli* and 13mm for *P. aeruginosa*. MRSA strain was resistant to the test drug making IZD 11mm and no inhibition zone was observed for *Candida albicans*. The MIC and MLC for *S. aureus* were of the same concentration (6 X 50μl) showing zero growth after that point. It can be concluded that *Triphala ashchotana* is effective in controlling acute conjunctivitis caused by *S. aureus* and the dosage required is 6 X 50 μl (6 drops). *Triphala* can also be used as a prophylactic agent against acute conjunctivitis.

**Keywords**: *Triphala Ashchyotana*, conjunctivitis

**Corresponding E-mail**: tadayarathna@gmailcom